Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

Rectal Cancer Clinical Trial

Official title:

Phase 2 Study of Total Neoadjuvant mFOLFOX and Short-Course Radiotherapy in Resectable Rectal Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04643366
• Other study ID #: MCC-18-14260
• Secondary ID: HM20020384NCI-20
• Status: Recruiting
• Phase: Phase 2
• Start date: January 28, 2021
• Est. completion date: January 31, 2033

Study information

• Verified date: January 2024
• Source: Virginia Commonwealth University
• Contact: Alison Ryan, NP
• Phone: 804-628-1936
• Email: ryanaa[@]vcu.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.

Description:

This trial involves 4 cycles of systemic chemotherapy followed by short-course RT with concurrent 5-FU neoadjuvant chemoradiotherapy (CRT) and subsequent consolidation with 4 cycles of systemic chemotherapy prior to surgery or, for those who achieve cCR, the option of non-operative active surveillance.Three-year disease free survival (DFS) defined as the percentage of patients alive without recurrence of disease at 3 years measured from the date of clinical complete response (cCR) or date of total mesorectal excision (TME) at surgery (whichever is earlier).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 54
• Est. completion date: January 31, 2033
• Est. primary completion date: January 31, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathologic diagnosis of adenocarcinoma of the rectum (diagnosis by tissue biopsy) within 90 days prior to registration. At least a portion of the tumor must be located below the peritoneal reflection or begin within 12 cm of the anal verge on flexible endoscopy

• Clinically staged (AJCC 8th ed.) T3-4 N0 M0 or T any N1-2 M0 based upon the following minimum diagnostic workup:

• Colonoscopy, unless patient presents with an obstructing lesion

• Within 30 days prior to registration:

• History/physical examination

• Imaging to exclude distant metastases: either contrast-enhanced CT of the chest, abdomen, and pelvis or whole-body PET-CT or MRI

• Pelvic MRI (preferred) or transrectal ultrasound (TRUS) for T staging

• ECOG Performance Status =1

• Age = 18 years

• Adequate bone marrow function defined as follows:

• Absolute neutrophil count (ANC) = 1,200 cells/mm3

• Platelets = 100,000 cells/mm3

• Hemoglobin = 8.0 g/dL (Note: The use of transfusion or other intervention to achieve Hgb =8.0 g/dL is acceptable.)

• Adequate liver and renal function defined as follows:

• AST and alkaline phosphatase < 2.5 x upper limit of normal (ULN)

• Bilirubin = 2.5 ULN

• Calculated creatinine clearance (CrCl) > 30 mL/min using Cockcroft-Gault formula as calculated by the standard Cockcroft-Gault equation using age, actual weight, creatinine, and gender

• Must be deemed a candidate for curative resection by the surgical oncologist who will be performing the operation

• Women of childbearing potential (WCBP) must have a negative serum pregnancy test performed within 7 days prior to the start of chemotherapy.

• WCBP and men must agree to use a medically accepted form of birth control during the treatment and for 3 months following completion of chemotherapy.

• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Prior RT that would result in overlap of RT fields with the planned study treatment

• Clinically significant cardiac disease, including major cardiac dysfunction, that in the opinion of the treating medical oncologist would preclude them from receiving systemic therapy with 5-fluorouracil, leucovorin or oxaliplatin.

• Serious (ie, = grade 3) uncontrolled infection

• Pulmonary or respiratory condition that, in the opinion of the treating medical oncologist would preclude them from receiving systemic therapy with 5-fluorouracil, leucovorin or oxaliplatin.

• Major surgery within 28 days of study enrollment (other than diverting colostomy)

• History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis) requiring significant intervention (eg, hospitalization, surgery, immunosuppressive medications) that would, in the opinion of the investigator, preclude study therapy

• Prior known allergic reaction to 5-fluorouracil, leucovorin, or oxaliplatin

• Known dipyrimidine dehydrogenase deficiency (DPD)

• Any evidence of distant metastases (M1)

• Pregnant or breast feeding

• Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

Related Conditions & MeSH terms

• Rectal Cancer
• Rectal Neoplasms

Intervention

Drug:
• Chemotherapy
Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)

Radiation:
• Radiation Therapy
Pelvic Intensity-modulated radiation therapy (IMRT)

Locations

Country	Name	City	State
United States	Virginia Cancer Institute	Richmond	Virginia
United States	Virginia Commonwealth University Massey Cancer Center	Richmond	Virginia
United States	VCU Community Memorial Healthcenter	South Hill	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Virginia Commonwealth University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Three-year disease free survival (DFS)	The three-year disease free survival (DFS) defined as the number of patients alive without recurrence of disease at 3 years measured from the date of clinical complete response (cCR) or date of total mesorectal excision (TME) at surgery (whichever is earlier).	3 years after end of treatment
Secondary	Pathologic complete response (pCR) rate	The number of patients that achieve pathologic complete response(pCR)(defined as negative surgical margins and no evidence of residual viable tumor) at time of total mesorectal excision (TME).	3 Years after end of treatment
Secondary	Clinical complete response (cCR) following total neoadjuvant therapy (TNT) based on tumor response	Determine the cCR using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), in patients evaluable for response	3 Years after end of treatment
Secondary	The number of Adverse events (AEs) per participant	The number of Adverse events (AEs) per participant characterized and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v. 5.0)	39 Months
Secondary	Progression (PFS) Rate	PFS defined as the time from initiation of chemotherapy until date of progression	3 Years after end of treatment
Secondary	Overall Survival (OS) Rate	OS defined as the time from initiation of chemotherapy until death by any cause.	3 Years after end of treatment
Secondary	Number of patients who do not require an ostomy at time of surgery	After neoadjuvant therapy is complete patients will undergo assessment of disease status prior to determination of whether they will proceed to surgical resection or active surveillance	116 Days